Introduction {#sec1}
============

Nearly ten years ago percutaneous renal denervation (RDN) was introduced in clinical trials as a possible method of interventional treatment of resistant hypertension. The promising results of the first clinical trials initiated the intensive development of this method. The Symplicity HTN-1 trial was the first in-human study confirming the safety of the procedure in 45 patients, being then extended to a single-arm trial involving 138 patients. Symplicity HTN-2 was the first randomized controlled trial (RCT). In both trials, significant and sustained blood pressure (BP) reductions achieved after renal denervation (approximately 25 mm Hg) and favorable procedural safety brought hope for a long-term benefit from the treatment in terms of cardiovascular risk reduction \[[@cit0001]--[@cit0003]\].

Symplicity-HTN 3 trial -- why did it fail? {#sec2}
==========================================

Symplicity HTN-3 was the first study with sham treatment implementation. In brief, 535 patients with resistant hypertension were randomly assigned in a 2 : 1 ratio to undergo renal artery denervation or a sham procedure \[[@cit0004]\]. After 6 months, the differences in office BP and ambulatory blood pressure monitoring (ABPM) reductions between RDN and sham were not significant (14.1 vs. 11.7 mm Hg; 7.75 vs. 4.79 mm Hg respectively). The disappointing results of the trial raised some concerns for the efficacy of the procedure and initiated a discussion about potential reasons for this failure \[[@cit0005]--[@cit0007]\].

First of all, the inclusion criterion of resistant hypertension was based only on systolic office and ambulatory BP measurements. As a result, almost 1/3 of the patients were included in the study on the basis of isolated systolic hypertension, independently of their diastolic blood pressure. Additional analysis of these patients, characterized by increased arterial stiffness and diminished sympathetic nervous system activity, revealed that the effect of RDN was less pronounced as compared to the subjects with systolic-diastolic resistant hypertension.

Secondly, despite the protocol requirements, the anti-hypertensive drug regimen was changed during the follow-up period in 40% of patients. In might have had an impact on the results obtained after the treatment.

Moreover, the experience of 112 operators performing the study procedures in 88 American sites was rather modest. It is of note that more than half of them carried out only 1 or 2 procedures in this trial, being just at the beginning of their learning process. On can speculate that if the reductions of the blood pressure had been similar to those obtained in previous studies (with more experienced operators), the difference would have been statistically significant and the HTN-3 study would have been successfully completed.

In summary, several factors had a substantial impact on the results of the HTN-3 trial. Therefore, the protocols of the next studies had to be modified taking into account the conclusions from the HTN-3 analyses and new modern devices enabling complete damage of the sympathetic nerve fibers were required.

New devices {#sec3}
===========

During the last years, two companies introduced into clinical studies new RDN devices.

The Symplicity Spyral multi-electrode renal denervation catheter (Medtronic US), is a 4 Fr over-the-wire, helical-shaped catheter, whose distal tip is deployed by retracting the guide wire into the catheter lumen ([Figure 1](#f0001){ref-type="fig"}). Its multi-electrode and helical design enables delivery of radiofrequency energy from the generator to each quadrant of the vessel (simultaneously with all four electrodes), thus maximizing damage to the sympathetic nerves around the renal vessel in a consistent four-quadrant ablation pattern. This device conforms to a wide range of artery shapes and sizes (3 mm to 8 mm in diameter), eliminating the need for multiple catheters per procedure. The Symplicity G3 generator independently controls the temperature and impedance during 60-second treatments.

![Spyral RDN system: the generator, the Spyral catheter, the catheter deployed in the renal artery](PWKI-14-34226-g001){#f0001}

The Paradise system (ReCor Medical, US) consists of a 6 Fr over-the-wire, multi-lumen catheter shaft with a cylindrical piezoelectric ceramic transducer placed inside an inflatable balloon at the distal end of the catheter combined with a portable generator ([Figure 2](#f0002){ref-type="fig"}). The cylindrical transducer converts the electrical energy delivered from the generator to ultrasound energy, which is then radiated into the renal artery tissue. Due to the physics of sound propagation, direct tissue contact with the ultrasound source is not required for energy transmission. Each energy application lasts only 7 s. The generator is designed to control energy delivery and fluid management inside the balloon. The balloon-based fluid transfer mechanism is implemented for cooling the endothelial and medial layers of the arterial wall to preserve the integrity of the vessel wall during the energy delivery. This endovascular catheter achieves a circumferential ring of ablation at a depth of 1--6 mm from the vessel lumen, which is the expected location of the efferent and afferent renal nerves in the adventitia \[[@cit0008]--[@cit0010]\]. The different balloon sizes enable arteries from 3.5 mm up to 8 mm in diameter to be treated.

![Paradise System: the generator, the Paradise catheter, the mechanism of action](PWKI-14-34226-g002){#f0002}

Second-generation sham-controlled trials {#sec4}
========================================

Taking into account the conclusions of the Symplicity HTN-3 study analysis, need for significant modification of the next generation sham-controlled randomized controlled trials' protocols was widely postulated. After the second European Clinical Consensus Conference for device-based therapies for hypertension, new recommendations for the next generation of sham-controlled RCT were published. The main principles assume at first the mandatory use of new devices and dedicated treatment recommendations. If monopolar radiofrequency renal denervation is used, four-quadrant ablation at each renal side is recommended. Furthermore, only experienced interventionalists from experienced centers should carry out the procedure, preferably in the absence of any medication, to assess the 'true' BP reduction of RDN. Witnessed intake of medication and/or medication adherence in each patient should be introduced in the study. The BP lowering efficacy of RDN should be assessed with 24-hour ambulatory blood pressure monitoring (ABPM) \[[@cit0011]\].

In the last 18 months the results of new RCTs using new radiofrequency or ultrasound based RDN catheters and including different populations of patients have been reported.

SPYRAL HTN trials {#sec4.1}
-----------------

SPYRAL-HTN is a multicenter project launched by Medtronic using the abovementioned new generation multi-electrode SPYRAL catheter. Two preliminary randomized trials -- SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED -- were designed, with modified inclusion and exclusion criteria \[[@cit0012]\]. The SPYRAL study included patients with office systolic BP in the range of 150--180 mm Hg, diastolic BP above 90 mm Hg (patients with isolated systolic hypertension were excluded) and 24-hour systolic BP in the range of 140--170 mm Hg during the use of one to three antihypertensive drugs used for a period of at least 6 weeks (ON-MED study) or after the gradual withdrawal of antihypertensive drugs (OFF-MED study). In both studies, the concentration of antihypertensive drug metabolites in urine was assessed, either to confirm patients' adherence to antihypertensive therapy (ON-MED study) or to confirm not taking antihypertensive drugs (OFF-MED study). In the actively treated study group 'total' RDN (the largest possible number of energy applications in the main renal arteries within their trunk and their distal branches, as well as in additional renal arteries with a diameter of at least 3 mm) and in the control group sham treatment were performed. The results of the SPYRAL HTN-OFF MED study were presented at the ESC Congress in Barcelona, and then published in Lancet in August 2017 \[[@cit0013]\]. Townsend et al. presented an analysis of 80 patients remaining off antihypertensive medications throughout a 3-month follow-up. Thirty-eight patients had been previously randomly assigned to the RDN group and in 42 patients a sham procedure had been performed. At the 3-month follow-up, in the RDN group a significant reduction in office systolic and diastolic BP values was observed (--10 mm Hg and --5.3 mm Hg respectively). Also in ABPM, both systolic and diastolic BP decreased significantly (--5.5 mm Hg and --4.8 mm Hg, respectively). The sham treatment was not associated with a significant change in BP levels during the follow-up. The observed decrease in systolic BP was not as high as in the first-generation RCT. It should be noted however that in the SPYRAL HTN-OFF MED study patients with baseline systolic BP \> 180 mm Hg were not included, which should be taken into consideration as high baseline systolic BP is one of the strongest predictors of BP response to RDN. The results of the SPYRAL HTN-OFF MED study confirmed the validity of further research on RDN, including the continuation of the SPYRAL HTN-ON MED trial. Four hundred sixty-seven patients were screened and 80 fulfilled the inclusion/exclusion criteria of this study. The results were presented in May 2018 at the European Congress of Interventional Cardiologists Euro-PCR and subsequently published in Lancet \[[@cit0014]\]. Thirty-eight patients with poorly controlled hypertension on one to three antihypertensive drugs in stable doses for at least 6 weeks were randomly assigned to the RDN group (with the same technique as in the OFF MED study) and in 44 patients a sham procedure was performed. Office and 24-hour ambulatory BP decreased significantly from baseline to 6 months in the RDN group (--9.4/--5.3 mm Hg and --9.0/--6.0 mm Hg, respectively). Similarly to the SPYRAL HTN-OFF MED study, in the HTN-ON MED study, the sham procedure was not associated with a significant change in BP at 6 months. Interestingly, despite the fact that the patients were informed about the measurements of drug concentrations, about half of the patients did not comply with the medical recommendations regarding the use of antihypertensive drugs.

In both SPYRAL HTN studies there were no significant procedure-associated adverse events, which confirms the safety of RDN using a new generation multi-electrode catheter.

RADIANCE-HTN SOLO study {#sec4.2}
-----------------------

The results of the RADIANCE-HTN SOLO study in which the new ultrasound catheter Paradise was implemented were presented in May 2018 in *Lancet* \[[@cit0015]\]. RADIANCE-HTN SOLO was a multicenter, international, single-blind, randomized, sham-controlled trial including patients with combined systolic--diastolic hypertension after a 4-week discontinuation of up to two antihypertensive medications and suitable renal artery anatomy. One hundred and forty-six patients meeting the inclusion/exclusion criteria were randomized to undergo RDN (*n* = 74) or a sham procedure (*n* = 72).

After 2 months the reduction in daytime ambulatory systolic BP was greater with RDN than with the sham procedure (--8.5 vs. --2.2 mm Hg, respectively). The primary end-point -- baseline-adjusted difference between groups (--6.3 mm Hg, 95% CI: --9.4 to --3.1, *p* = 0.0001) -- was met. No major adverse events were reported in either group. In summary, in the RADIANCE-HTN SOLO study the efficacy and short-time safety of endovascular ultrasound RDN was confirmed at 2 months in patients with combined systolic--diastolic hypertension in the absence of medications.

Comparison of available technologies {#sec5}
====================================

Recently, Fengler *et al.* presented the results of the first trial comparing three different techniques and technologies for catheter-based RDN. One hundred and twenty patients with resistant hypertension were randomized in a 1 : 1 : 1 manner to receive either treatment with 1) radiofrequency RDN of the main renal arteries (39 patients), 2) radiofrequency RDN of the main renal arteries, side-branches and accessories (39 patients), or 3) an endovascular ultrasound-based RDN of the main renal artery (42 patients). At 3 months, daytime systolic and diastolic BP decreased significantly in the overall cohort and also within each treatment group (*p* \< 0.001). However, the systolic daytime blood pressure was significantly more reduced in the ultrasound ablation group than in the radiofrequency ablation group of the main renal artery (--13.2 ±13.7 vs. --6.5 ±10.3 mm Hg). No significant difference was found between the ultrasound RDN and the side branch ablation groups, nor between two strategies of radiofrequency RDN. The authors conclude that endovascular ultrasound based RDN seems to be superior to radiofrequency ablation of the main renal arteries only, whereas a combined approach of radiofrequency ablation of the main arteries, accessories and side branches was not \[[@cit0016]\].

European Society of Hypertension Position Paper on renal denervation 2018 {#sec6}
=========================================================================

The promising results of the second-generation RCTs confirming safety and short-time efficacy of RDN in new groups of patients and using new technologies prompted European Society for Hypertension (ESH) experts to develop an up-to-date position paper on RDN \[[@cit0017]\]. In all three studies, in patients who underwent RDN a similar, significant decrease in BP during the follow-up period was observed ([Table I](#t0001){ref-type="table"}). ESH experts emphasize, however, that some questions about RDN remain unanswered. The heterogeneity of the blood pressure-lowering response point to the clinical need to identify predictors for efficacy, and questions on long-term safety could not be answered due to the short duration of the sham-controlled RCTs.

###### 

Comparison of the Symplicity HTN-3 and second-generation sham-controlled trials

  Study                                   SYMPLICITY HTN-3                                                                                                                                      SPYRAL HTN-OFF MED \[[@cit0013]\]                                                                                   SPYRAL HTN-ON MED \[[@cit0014]\]                                                                                                           RADIANCE-HTN SOLO \[[@cit0015]\]                                                                  
  --------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------- --------------
  **Device used**                         Uni-electrode radiofrequency catheter                                                                                                                 Multi-electrode radiofrequency catheter                                                                             Multi-electrode radiofrequency catheter                                                                                                    Ultrasound-based catheter                                                                         
  **Main inclusion criteria of BP**       Office SBP ≥ 160 mm Hg and 24 h ambulatory SBP ≥ 135 mm Hg on 3 ≥ anti-hypertensive medications at maximally tolerated dosage, including a diuretic   Office SBP 150--179 mm Hg and DBP ≥ 90 mm Hg and 24-hour ambulatory SBP 140--169 mm Hg off antihypertensive drugs   Office SBP 150--179 mm Hg and DBP ≥ 90 mm Hg and 24-hour ambulatory SBP 140--169 mm Hg on 1--3 antihypertensive drugs including diuretic   Ambulatory 24-hour SBP 135--169 mm Hg and 24-hour DBP 85--104 mm Hg, off antihypertensive drugs   
  **No. of patients/controls included**   364/171                                                                                                                                               38/42                                                                                                               38/42                                                                                                                                      74/72                                                                                             
  **Sham treatment?**                     No                                                                                                                                                    Yes                                                                                                                 Yes                                                                                                                                        Yes                                                                                               
  **Follow-up period \[months\]**         6                                                                                                                                                     3                                                                                                                   6                                                                                                                                          2                                                                                                 
  **BP lowering effect \[mm Hg\]**        **Office SBP/DBP**                                                                                                                                    --14.1/--6.6                                                                                                        --10.0/--5.3                                                                                                                               --9.4/--5.2                                                                                       --10.8/--5.5
  **24-hour ambulatory SBP/DBP**          --6.75/--4.1                                                                                                                                          --5.5/--4.8                                                                                                         --9.0/--6.0                                                                                                                                --7.0/--4.4                                                                                       
  **Daytime ambulatory SBP/DBP**          NA                                                                                                                                                    NA                                                                                                                  --8.8/--6.3                                                                                                                                --8.5/--5.1                                                                                       

BP -- blood pressure, SBP -- systolic blood pressure, DPB -- diastolic blood pressure, NA -- not available.

It should also be noted that as afferent and efferent renal nerves also play a crucial role in cardiovascular, metabolic and renal diseases other than hypertension, RDN may offer a new interventional treatment option for various conditions (obstructive sleep apnea (OSA), congestive heart failure, atrial fibrillation, chronic renal failure, diabetes).

Renal denervation and obstructive sleep apnea {#sec7}
=============================================

Considering RDN as a potential treatment option of various conditions other than hypertension, interesting data on the use of RDN in patients with OSA coexisting with resistant hypertension have been reported recently. In a proof-of-concept, observational study Witkowski *et al.* evaluated the effects of this procedure on BP and sleep apnea severity in patients with resistant hypertension and sleep apnea. Ten patients with refractory hypertension and sleep apnea (7 men and 3 women; median age: 49.5 years) underwent RDN and completed 3-month and 6-month follow-up evaluations, including polysomnography, selected blood chemistries, and BP measurements. Antihypertensive regimens were not changed during the 6 months of follow-up. Three and 6 months after RDN, decreases in office systolic and diastolic BPs (median: --34/--13 mm Hg for systolic and diastolic BPs at 6 months; both *p* \< 0.05) as well as a decrease in apnea-hypopnea index (AHI) at 6 months after RDN (median: 16.3 vs. 4.5 events per hour; *p* = 0.059) were observed \[[@cit0018]\]. In their conclusions Witkowski *et al.* postulated that RDN may be a potentially useful option for selected patients with true resistant hypertension and moderate-to-severe OSA. The same group of authors designed a randomized controlled clinical trial based on a larger group of patients to confirm initial proof-of-concept data \[[@cit0019]\]. Sixty patients with true resistant hypertension coexisting with moderate-to-severe OSA (AHI ≥ 15) were randomly allocated to the RDN group (30 patients) and to the control group (30 patients). The primary end point was reduction in office systolic BP at 3 months. Secondary end points included reduction in diastolic office and ambulatory BP, change in apnea/hypopnea index and biochemical measurements at 3 months, and change in echocardiographic measurements at 6 months. At 3 months in the RDN group, both office and ambulatory BP were significantly reduced, and a significant decrease in OSA severity (AHI, 39.4 vs. 31.2 events per hour; *p* = 0.015) was observed. The between-group difference in apnea/hypopnea index change was significant at 0.05. At 6 months in the RDN group, reductions in office and ambulatory BP were sustained and were accompanied by significant improvement in echocardiographic measures of global longitudinal strain. There were no differences in metabolic variables in the follow-up between the groups. Ewa Warchol-Celinska *et al.* concluded that for the first time in an RCT, RDN lowered both office and ambulatory BP in patients with resistant hypertension coexisting with OSA, which was accompanied by improvement of the clinical severity of OSA. The obtained data were in concordance with the post hoc analyses from Symplicity-HTN-3 \[[@cit0020]\] and Global Symplicity Registry studies \[[@cit0021]\], suggesting that patients with OSA may be particularly responsive to RDN therapy. In another prospective study including twenty resistant hypertensive patients with OSA, moderate blood pressure reduction was achieved after renal denervation with no significant changes in sleep apnea severity \[[@cit0022]\]. A summary of these trials is presented in [Table II](#t0002){ref-type="table"}. Further studies are undoubtedly warranted to assess the impact of RDN on sleep apnea and its relation to BP decline and cardiovascular risk.

###### 

Summary of renal denervation trials in patients with concomitant obstructive sleep apnea

  Study                                                                   Witkowski *et al*. \[[@cit0018]\]                                                                                            SYMPLICITY HTN-3 \[[@cit0005]\]                                                                                                                                  GLOBAL SYMPLICITY REGISTRY \[[@cit0021]\]              Daniels *et al*. \[[@cit0022]\]                                                                                              Warchol-Celinska *et al*. \[[@cit0019]\]                                                                                                                         
  ----------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------
  **Type of study**                                                       Proof-of-concept study                                                                                                       Post-hoc analysis of randomized, sham-controlled study                                                                                                           Post-hoc analysis of registry data                     Single-arm prospective study                                                                                                 Randomized, controlled prospective study                                                                                                                         
  **Year of publication**                                                 2011                                                                                                                         2016                                                                                                                                                             2017                                                   2017                                                                                                                         2018                                                                                                                                                             
  **Device used**                                                         Uni-electrode radiofrequency catheter                                                                                        Uni-electrode radiofrequency catheter                                                                                                                            Uni-electrode radiofrequency catheter                  Uni-electrode or multielectrode radiofrequency catheter                                                                      Uni-electrode radiofrequency catheter                                                                                                                            
  **Main inclusion criteria of uncontrolled or resistant hypertension**   Office SBP ≥ 160 mm Hg despite at least 3 antihypertensive medications at maximally tolerated dosage, including a diuretic   Office SBP ≥ 160 mm Hg and 24 h ambulatory SBP ≥ 135 mm Hg despite at least 3 antihypertensive medications at maximally tolerated dosage, including a diuretic   All real-world patients with office SBP \> 140 mm Hg   Office SBP ≥ 160 mm Hg despite at least 3 antihypertensive medications at maximally tolerated dosage, including a diuretic   Office SBP ≥ 140 mm Hg and 24 h ambulatory SBP ≥ 135 mm Hg despite at least 3 antihypertensive medications at maximally tolerated dosage, including a diuretic   
  **Method of OSA confirmation**                                          AHI ≥ 5 events/h in polysomnography                                                                                          Self-reported                                                                                                                                                    Self-reported                                          AHI ≥ 15 events/h in polysomnography                                                                                         AHI \> 15 events/h in polysomnography                                                                                                                            
  **No. of patients/controls included**                                   10/--                                                                                                                        94/54                                                                                                                                                            205/--                                                 20/--                                                                                                                        30/30                                                                                                                                                            
  **Follow-up \[months\]**                                                6                                                                                                                            6                                                                                                                                                                6                                                      6                                                                                                                            3                                                                                                                                                                
  **BP lowering effect \[mm Hg\]**                                        **Office SBP/DBP**                                                                                                           --34/--13                                                                                                                                                        --17.0/--6.7                                           --14/NA                                                                                                                      --6.6/--6.5                                                                                                                                                      --22/--8
  **24-hour ambulatory SBP/DBP**                                          --6.0/NA                                                                                                                     --5.0/--3.7                                                                                                                                                      --4.9/NA                                               --8.3/--6.2                                                                                                                  --12/--7                                                                                                                                                         
  **Daytime ambulatory SBP/DBP**                                          --7.0/NA                                                                                                                     --5.2/NA                                                                                                                                                         NA                                                     NA                                                                                                                           --14/--9                                                                                                                                                         
  **AHI change**                                                          --11.8 events/h                                                                                                              Not measured                                                                                                                                                     Not measured                                           --0.9 events/h                                                                                                               --8.2 events/h                                                                                                                                                   

BP -- blood pressure, SBP -- systolic blood pressure, DPB -- diastolic blood pressure, OSA -- obstructive sleep apnea, AHI -- apnea-hypopnea index, NA -- not available.

Conclusions {#sec8}
===========

Over the last months, the results of important RCTs using sham treatment have been published, confirming the efficacy and safety of RDN in previously uninvestigated groups of patients -- patients with hypertension after drug withdrawal, patients with poorly controlled hypertension despite 1--3 antihypertensive drugs, as well as in patients with resistant hypertension co-existing with obstructive sleep apnea. Despite these promising new results that again widely open up the field of RDN, ESH experts in the current position underline that in accordance with the current recommendations of the European Guidelines 2018 "device based therapies are not recommended in general for the treatment of HTN at least at the current moment" \[[@cit0023]\]. However, they also recommend conducting RDN in the framework of "clinical studies and sham-controlled RCT (to) further provide safety and efficacy in a larger set of patients". So far the number of patients included in the trials is small, the follow-up duration short and several important questions remain unanswered. The upcoming trials, including pivotal studies, presented in [Table III](#t0003){ref-type="table"} \[[@cit0024]--[@cit0026]\], should provide answers to many questions regarding RDN. It is also of note that RDN may offer a new interventional treatment option for various conditions other than hypertension, especially obstructive sleep apnea.

###### 

Ongoing and upcoming trials on renal denervation

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                     RADIANCE-HTN TRIO \[[@cit0024]\]                                                                                                                                         REQUIRE \[[@cit0024]\]                                                                                          RADIANCE II (Pivotal study) \[[@cit0025]\]                                 SPYRAL PIVOTAL \[[@cit0026]\]
  ----------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  **Type of study**                         Multicenter, blinded, randomized (1 : 1)                                                                                                                                 Multicenter (Japan, Korea), blinded, randomized (1 : 1)                                                         Multicenter (Europe, US), blinded, randomized (2 : 1)                      Multicenter (Europe, US, Japan), blinded, randomized (1 : 1)

  **Device used**                           Ultrasound-based catheter                                                                                                                                                Ultrasound-based catheter                                                                                       Ultrasound-based catheter                                                  Multi-electrode radiofrequency catheter

  **Sham controlled?**                      Yes                                                                                                                                                                      Yes                                                                                                             Yes                                                                        Yes

  **Number of participants planned**        229                                                                                                                                                                      140                                                                                                             225                                                                        433

  **Main inclusion criteria of BP**         Office BP ≥ 140/90 mm Hg and ambulatory 24-hour SBP 135--169 mm Hg and 24-hour DBP 85--104 mm Hg on at least 3 antihypertensive drugs including diuretic (single-pill)   Office BP ≥ 150/90 and ambulatory 24-hours SBP ≥ 140 on at least 3 antihypertensive drugs, including diuretic   Ambulatory daytime BP 135--169/85--104 mm Hg off antihypertensive agents   Ambulatory 24-hour SBP 135--170 mm Hg and 24-hour DBP 85--105 mm Hg off antihypertensive drugs

  **Primary end-point**                     Daytime ambulatory SBP change at 2 months                                                                                                                                24-hour SBP change at 3 months                                                                                  1 -- incidence of major adverse events\                                    Office SBP 150--179 mm Hg and DBP ≥ 90 mm Hg and 24-hour ambulatory SBP 140--169 mm Hg off antihypertensive drugs
                                                                                                                                                                                                                                                                                                                                     2 -- daytime ambulatory SBP change at 2 months                             

  **End of enrollment expected \[year\]**   End of 2019                                                                                                                                                              End of 2019                                                                                                     End of 2020                                                                End of 2020

  **Results expected \[year\]**             2020                                                                                                                                                                     2020                                                                                                            2021                                                                       2021
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

US -- United States, BP -- blood pressure, SBP -- systolic blood pressure, DPB -- diastolic blood pressure.
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